BridgeBio Oncology Therapeutics (BBOT) Non-Current Deffered Revenue (2024 - 2025)

BridgeBio Oncology Therapeutics (BBOT) posted Non-Current Deffered Revenue of $5.5 million for Q2 2025, little changed sequentially from $5.5 million in Q1 2025, and little changed YoY from $5.5 million in Q2 2024.

BridgeBio Oncology Therapeutics (BBOT) Non-Current Deffered Revenue (2024 - 2025) Analysis & Trends

BridgeBio Oncology Therapeutics has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $5.5 million in Q2 2025.

  • Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $5.5 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $5.5 million (changed 0.0% YoY) and the FY2024 annual result came in at $5.5 million, changed N/A from the prior year.
  • Non-Current Deffered Revenue steadied at $5.5 million in Q2 2025 per BBOT's latest filing, from $5.5 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $5.5 million in Q1 2024 and troughed at $5.5 million in Q1 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 BridgeBio Oncology Therapeutics 726.38 Mn 500.67 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 5.52 Mn
Mar 31, 2025 5.52 Mn
Dec 31, 2024 5.52 Mn
Sep 30, 2024 5.52 Mn
Jun 30, 2024 5.52 Mn
Mar 31, 2024 5.52 Mn